Profile data is unavailable for this security.
About the company
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
- Revenue in GBP (TTM)0.00
- Net income in GBP-1.72m
- Incorporated2007
- Employees67.00
- LocationCizzle Biotechnology Holdings PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
- Phone+44 20 7469 0930Fax+44 23 8123 0382
- Websitehttps://cizzlebiotechnology.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
ReNeuron Group Plc | 249.00k | -5.07m |
Fusion Antibodies PLC | 1.58m | -2.84m |
IXICO PLC | 6.00m | -1.87m |
TheraCryf PLC | 396.00k | -3.14m |
ValiRx Plc | 9.60k | -2.04m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
Destiny Pharma PLC | 0.00 | -5.66m |
ImmuPharma PLC | 0.00 | -2.92m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Synairgen plc | 0.00 | -8.41m |
Bivictrix Therapeutics PLC | 0.00 | -2.55m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Unicorn Asset Management Ltd.as of 31 May 2024 | 34.20k | 0.01% |